RECRUITING

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).

Official Title

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Quick Facts

Study Start:2022-08-22
Study Completion:2024-08-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06223607

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * ≥ 18 years
  2. * PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
  3. * Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI
  4. * At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
  1. * Death within 48 hours post-PCI
  2. * DAPT prior to cardiac catheterization

Contacts and Locations

Study Contact

Bethany Brauer
CONTACT
214-947-4681
mhsirb@mhd.com
Colette Ngo Ndjom
CONTACT
214-947-1289
mhsirb@mhd.com

Principal Investigator

Jessica Rago Crotty, Pharm D
PRINCIPAL_INVESTIGATOR
Methodist Midlothian Medical Center

Study Locations (Sites)

Methodist Dallas Medical Center
Dallas, Texas, 75203
United States

Collaborators and Investigators

Sponsor: Methodist Health System

  • Jessica Rago Crotty, Pharm D, PRINCIPAL_INVESTIGATOR, Methodist Midlothian Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-08-22
Study Completion Date2024-08-22

Study Record Updates

Study Start Date2022-08-22
Study Completion Date2024-08-22

Terms related to this study

Additional Relevant MeSH Terms

  • Baseline Thrombocytopenia